

Guido Stirnimann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8831095/publications.pdf>

Version: 2024-02-01

43
papers

647
citations

566801

15
h-index

610482

24
g-index

43
all docs

43
docs citations

43
times ranked

1107
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 820724.	1.6	22
2	Consensus care recommendations for alfapump® in cirrhotic patients with refractory or recurrent ascites. <i>BMC Gastroenterology</i> , 2022, 22, 111.	0.8	5
3	Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump. <i>Liver International</i> , 2022, 42, 2247-2259.	1.9	4
4	Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. <i>Journal of Autoimmunity</i> , 2021, 116, 102578.	3.0	17
5	Determination of bile acids from human gallbladder by 1 H-MRS Protocol optimization and estimation of reproducibility. <i>NMR in Biomedicine</i> , 2021, 34, e4432.	1.6	2
6	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , 2021, 41, 2759-2767.	1.9	5
7	Aspects of albendazole metabolism in western lowland gorillas (<i>Gorilla gorilla gorilla</i>) compared to humans and other species assessed by HPLC, LC-MS, and chiral electrokinetic chromatography. <i>Separation Science Plus</i> , 2021, 4, 347-356.	0.3	0
8	P041 Tandem mass tag-based quantitative proteomic profiling identifies novel putative serum biomarkers for the diagnosis of drug-induced liver injury in patients. , 2021, , .		1
9	Treatment of refractory ascites with an automated low flow ascites pump in patients awaiting liver transplantation. <i>Journal of Liver Transplantation</i> , 2021, 4, 100037.	0.2	2
10	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study. , 2021, 59, .		1
11	Management of transthyretin amyloidosis. <i>Swiss Medical Weekly</i> , 2021, 151, w30053.	0.8	7
12	Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1151-1158.	1.9	17
13	Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications. <i>United European Gastroenterology Journal</i> , 2020, 8, 961-969.	1.6	8
14	Tailored access to the hepatobiliary system in post-bariatric patients: a tertiary care bariatric center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 5469-5476.	1.3	8
15	Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. <i>Hepatology</i> , 2020, 71, 2135-2148.	3.6	46
16	Hyper-coagulability in obese patients accurately identified by combinations of global coagulation assay parameters. <i>Thrombosis Research</i> , 2020, 187, 91-102.	0.8	10
17	Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. <i>Swiss Medical Weekly</i> , 2020, 150, w20364.	0.8	10
18	Mental Illness Has a Negative Impact on Weight Loss in Bariatric Patients: a 4-Year Follow-up. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 232-238.	0.9	14

#	ARTICLE	IF	CITATIONS
19	First Clinical Case of In Vivo Acquisition of DHA-1 Plasmid-Mediated AmpC in a Salmonella enterica subsp. enterica Isolate. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8
20	Nutritional Challenges in Patients with Advanced Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1926.	1.0	18
21	Cirrhosis and Autoimmune Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 49-58.	0.4	0
22	Adipopenia correlates with higher portal pressure in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 1672-1681.	1.9	26
23	Continuous low flow ascites drainage through the urinary bladder via the Alfapump system in palliative patients with malignant ascites. <i>BMC Palliative Care</i> , 2019, 18, 109.	0.8	9
24	Subacute cutaneous lupus erythematosus triggered by an antiviral treatment combination for hepatitis C virus infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e129-e131.	1.3	8
25	Recurrent and De Novo Autoimmune Hepatitis. <i>Liver Transplantation</i> , 2019, 25, 152-166.	1.3	59
26	Limited performance of subjective global assessment compared to computed tomography-determined sarcopenia in predicting adverse clinical outcomes in patients with cirrhosis. <i>Clinical Nutrition</i> , 2019, 38, 2696-2703.	2.3	32
27	Letter: innovative use of the alfapump system to treat small hepatocellular carcinoma – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 696-697.	1.9	0
28	Reply to: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thrombosis Research</i> , 2018, 164, 15-16.	0.8	3
29	C-Reactive Protein on Postoperative Day 1: a Predictor of Early Intra-abdominal Infections After Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 2760-2766.	1.1	17
30	Geoeidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 295-306.	2.9	12
31	Editorial: alfapump – an alternative to large-volume paracentesis for patients with refractory ascites? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 140-141.	1.9	0
32	Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients. <i>International Journal of Laboratory Hematology</i> , 2018, 40, e11-e14.	0.7	14
33	Should Sarcopenia Increase Priority for Transplant or Is It a Contraindication?. <i>Current Gastroenterology Reports</i> , 2018, 20, 50.	1.1	12
34	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1114-1120.	0.6	41
35	The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 1890-1896.	1.0	31
36	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 933-944.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Treatment of Malignant Ascites Using an Automated Pump Device. American Journal of Gastroenterology, 2018, 113, 1060-1061.	0.2	4
38	Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. British Journal of Clinical Pharmacology, 2017, 83, 1466-1475.	1.1	48
39	Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therapeutic Advances in Gastroenterology, 2017, 10, 283-292.	1.4	32
40	Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 981-991.	1.9	46
41	Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach. Journal of Viral Hepatitis, 2016, 23, 697-707.	1.0	3
42	Weighted Genetic Risk Scores and Prediction of Weight Gain in Solid Organ Transplant Populations. PLoS ONE, 2016, 11, e0164443.	1.1	7
43	Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy, 2014, 15, 2609-2622.	0.9	17